Dynavax Technologies | DVAX - Interest Expense On Debt


Dynavax Technologies reported $1.64M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Adma Biologics USD 1.68M 150K Sep/2025
Amgen USD 685M 9M Sep/2025
AstraZeneca USD 303M 38M Jun/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.58M 100K Sep/2025
Bristol-Myers Squibb USD 480M 5M Sep/2025
Dynavax Technologies USD 1.64M 2K Sep/2025
Gilead Sciences USD 254M 6M Jun/2025
Glaxosmithkline GBP 177.95M 6.05M Sep/2025
Merck USD 327M 22M Sep/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 281M 8M Sep/2025
Pfizer USD 652M 2M Sep/2025
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
TG Therapeutics USD 6.72M 4K Sep/2025
Vertex Pharmaceuticals USD 3.3M 400K Sep/2025